ProfileGDS5678 / 1439584_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 6% 6% 6% 5% 5% 6% 5% 6% 5% 6% 6% 6% 6% 6% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.121166
GSM967853U87-EV human glioblastoma xenograft - Control 22.098746
GSM967854U87-EV human glioblastoma xenograft - Control 32.101756
GSM967855U87-EV human glioblastoma xenograft - Control 42.051735
GSM967856U87-EV human glioblastoma xenograft - Control 52.042345
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.146876
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.094975
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.08056
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.065525
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.089336
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.082346
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.074126
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.092496
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.088216